Physician profile
Michael Forte
NPI 1437544723
$11,259.82
in general payments reported to CMS, 2019-2025
28 companies · $6,142 in 2025
The $6,142 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $85.18 · 2021: $129 · 2022: $575 · 2023: $636 · 2024: $3,693 · 2025: $6,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,701 · Travel and Lodging: $3,295 · Honoraria: $2,500 · Education: $775 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.03 |
| Travel and Lodging | $3,294.80 |
| Honoraria | $2,500.00 |
| Education | $775.00 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $5,432.93 | 2024-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Verona Pharma, INC. | $3,457.08 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $478.95 | 2020-2025 | Tezspire, Fasenra, Symbicort |
| Glaxosmithkline, LLC. | $445.30 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Ethicon INC. | $308.07 | 2022-2023 | Monarch Platform |
| Amgen INC. | $138.05 | 2022-2025 | Tezspire, Tavneos |
| Regeneron Healthcare Solutions, INC. | $113.86 | 2021-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.15 | 2021-2025 | Ofev |
| Fisher & Paykel Healthcare INC | $109.98 | 2024-2025 | Fisher & Paykel Healthcare |
| Mallinckrodt Hospital Products INC. | $99.19 | 2021-2025 | Acthar |
| Medtronic, INC. | $98.49 | 2023 | Illumisite |
| United Therapeutics Corporation | $82.94 | 2021-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $57.20 | 2022-2024 | |
| Genentech USA, INC. | $40.76 | 2023-2024 | Xolair |
| Insmed, INC. | $36.36 | 2023-2025 | Arikayce |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.31 | 2021-2024 | Keytruda |
| Electromed, INC. | $25.25 | 2023 | Smartvest |
| Baxter Healthcare | $23.25 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $22.66 | 2024 | Hyqvia |
| Pfizer INC. | $19.06 | 2022 | |
| Astellas Pharma US INC | $18.67 | 2023 | Cresemba |
| Bayer Healthcare Pharmaceuticals INC. | $18.47 | 2022 | |
| Abbvie INC. | $17.65 | 2023 | |
| Ani Pharmaceuticals, INC. | $15.09 | 2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $14.38 | 2022 | |
| Grifols USA, LLC | $13.35 | 2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $13.32 | 2023 | Yupelri |
| Eisai INC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Forte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.